Should You Buy Novavax Before Its Earnings Report?
Novavax (NASDAQ: NVAX) is inching closer to its goal: the commercialization of its coronavirus vaccine candidate. And that probably will be the focus of its earnings report on May 10. The biotech company is clinical-stage -- so it doesn't yet generate product revenue.
In recent days, we've heard news about potential Novavax vaccine deliveries to Europe by year-end. And Novavax just expanded its U.S. trial to include teens. Meanwhile, the shares have pulled back. They lost more than 20% in less than a week. Now, the question is whether it's a good idea to scoop up Novavax shares ahead of the upcoming earnings report. Let's take a closer look.
Image source: Getty Images.
Source Fool.com
